SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Shib2's story is nothing short of extraordinary, a tale of mystery, transformation, unity, and the unwavering determination of its community.  The Enigmatic Origins  Shib2 was born from the vision of a reclusive developer, known only by the pseudonym "Cipher." Unlike many cryptocurrency projects that begin with a whitepaper and a team of experts, Shib2 emerged quietly and mysteriously. Cipher, shrouded in anonymity, released the project's smart contract on the Ethereum blockchain with little fanfare. There were no pre-sales, no flashy marketing campaigns – just a single post on a cryptocurrency forum.  A Humble Beginning  In the early days, Shib2 was nothing more than a curiosity. Its smart contract was simple, allowing users to exchange Ethereum for Shib2 tokens. The project lacked a clear roadmap or a well-defined purpose, leaving many in the crypto community skeptical. Yet, something about Shib2 intrigued a small group of early adopters who saw its potential.  The Power of Community  What truly sets Shib2 apart is its community. As more people discovered the project, they formed a tight-knit group of enthusiasts. They began discussing its possibilities, proposing ideas, and volunteering their skills to help the project grow. Shib2 was no longer just Cipher's creation; it had become a collective endeavor.  Innovation and Transformation  The early days of Shib2 were marked by a rapid evolution. The community, driven by a desire to make Shib2 more than just a simple token, started developing new features and use cases. They introduced decentralized applications (dApps) that utilized Shib2, ranging from decentralized exchanges to governance platforms.  One of the project's standout features was the Shib2 NFT marketplace, where artists and creators could mint and trade non-fungible tokens. This marketplace quickly gained traction and became a hub for digital artists looking to explore the blockchain space.  Challenges and Growth  Of course, Shib2's journey was not without its challenges. The project faced its fair share of security issues and technical hurdles. Yet, the community's resilience shone through as they collectively tackled these obstacles. Audits were conducted, developers collaborated, and improvements were made. Shib2's journey was marked by a relentless pursuit of innovation and security.  Shib2 Today  Today, Shib2 stands as a testament to the power of community-driven projects. It has grown beyond anyone's expectations, boasting a thriving ecosystem of dApps, a robust NFT marketplace, and a dedicated community that continues to push the boundaries of what is possible in the world of blockchain technology.  Cipher, the enigmatic founder, still remains elusive, but their creation, Shib2, has taken on a life of its own. It has become a symbol of the potential for innovation, transformation, and unity within the cryptocurrency space.

SHIB2.0

SHIB2 is gaining traction as a new meme coin, with community members touting it as a second chance to capitalize on the Shiba Inu craze. Discussions revolve around its potential for high returns and rapid price fluctuations, with some cautioning about its volatile nature. The coin's increasing holder count and recent price action are also key talking points.

FLOKI is the utility token of the Floki Ecosystem. The Floki Ecosystem is a community-powered ecosystem that aims to give people control of their finances through four key utility offerings:  - The Valhalla NFT Metaverse Game. - The Floki University Crypto Education platform. - DeFi. - The FlokiPlaces NFT & Merchandise Marketplace.

Floki Token

Floki Token is trending, with the community actively discussing its potential amidst meme coin season and comparing its structure to other cryptocurrencies. There is excitement around upcoming project catalysts and how Floki could outperform other meme coins like DOGE and SHIB. Discussions also mention its potential for growth and real-world utility, with some community members highlighting on-chain metrics and staking rewards.

$LADYS coin has no association with Charlotte Fang or her creation Milady Maker. This token is simply paying homage to a meme we all love and recognize.  $LADYS is a meme coin with no intrinsic value or expectation of financial return. There is no formal team or roadmap. the coin is completely useless and for entertainment purposes only.  The project was initiated on 05 May 2023 and the contract was deployed on 07 May 2023.  The project will be launching a dapp on the official website for all holders of PEPE tokens and Milady Maker NFTs to claim $LADYS.

Milady

Milady is trending amidst mixed sentiment, with some traders anticipating potential Binance listing or a market correction while others express frustration over price stagnation and missed opportunities as other meme coins rally. Community members are actively debating the coin's future prospects, with some accumulating, while others are liquidating positions. Overall, the conversation revolves around whether Milady can capture renewed momentum in the current market.

$4CHAN is a meme token on the Ethereum Network.   4ChanToken represents a global crypto community that pays homage to the memetic powerhouses of the internet as Pepe, Doge, Shib and all major memes inventor combining them all into one super meme token that is $4CHAN. At its core, 4ChanToken embodies the untamed spirit of the notorious 4chan imageboard, where iconic memes are born, nurtured, and unleashed upon the world. With an unyielding spirit of irreverence and a touch of mischief, $4CHAN has emerged as the darling of meme enthusiasts, internet dwellers, and crypto aficionados alike.   The foundation of 4ChanToken lies in its community. We’ve harnessed the chaotic energy of this digital realm to create a currency that celebrates the power of memetic expression, empowering users to engage in a truly unique and decentralized economy. As a passionate supporter, you’ll join a vibrant ecosystem where dank memes and viral sensations are the lifeblood of commerce. 4ChanToken is more than just a digital currency – it’s the place where memes are born.  The ultimate playground for memelords and crypto degens. Based on the simplicity of holdrs/volume operating a store of value.  The identification of this value is best described as 'digital gold'. That $4chan can ultimately represent a superior store of value relative to all other forms of memecoins by embodying all memes in one token as the factual birthplace of all popular memes.

4Chan

4Chan Crypto is trending as the community rallies around its unique tokenomics, including blacklisted wallets designed to hedge against downturns.  Discussions revolve around its potential as the 'Bitcoin of memecoins,' its strong community, and the idea of achieving substantial gains due to its large number of zeros.  Some users promote its cultural significance and decentralized nature, contrasting it with more mainstream cryptocurrencies.

GME Ethereum

GME Ethereum is trending with community members actively discussing potential catalysts and a possible Roaring Kitty tweet, while others debate the coin's legitimacy and its connection to GameStop. Some traders are pointing to chart levels and anticipating a squeeze, while skeptical voices claim the coin is a scam with no actual affiliation with GameStop, citing a recent delisting from Revolut.

London-based Quant Network is set to revolutionise blockchain technology with the development of their blockchain operating system Overledger. The experienced team are determined to fulfil the original vision of the internet by creating an open trusted network for people, machines, and data to operate securely and safely.  Overledger -the first interoperable blockchain operating system that facilitates internet-scale development of decentralised, multi-chain applications. Overledger has the ability to unlock and distribute value and applications across current and future blockchains. It is an agnostic platform that connects the world's networks to blockchains and ensures you're not limited to any single a vendor or technology. Overledger is the only platform that facilitates the development of internet-scales development of decentralised, multi-chain applications.

Quant

Quant is gaining attention as discussions revolve around its role in tokenized deposits with major institutions and its potential in the evolving digital euro landscape. The community is closely watching key resistance levels, anticipating a breakout that could lead to triple-digit prices. Many believe QNT's focus on interoperability and real-world adoption positions it strongly in the long term, despite some short term pullbacks.

Keeta is a high-performance layer-1 blockchain designed to unify transactions across different blockchains and fiat payment systems, eliminating the need for costly intermediaries, reducing fees, and enabling near-instant settlements. With 400-millisecond transaction finality and the ability to process 10 million transactions per second, Keeta sets a new industry benchmark for speed and scalability.  Founded in 2022 and backed by Eric Schmidt, the former CEO of Google, Keeta has been engineered to meet the stringent regulatory and operational requirements of financial institutions. Its advanced on-chain compliance protocols, including KYC and AML, ensure security and regulatory adherence. Keeta’s architecture natively supports asset tokenization and digital identity, making it an ideal platform for stablecoins and real-world asset transfers.  By facilitating cross-chain transactions and interoperability with existing payment systems, Keeta bridges the gap between cryptocurrencies and fiat, enabling a secure, efficient, and compliant global financial ecosystem.

Keeta

Keeta (KTA) is trending due to community excitement around its potential as foundational infrastructure for TradFi, emphasized by its high throughput and compliance-aware design. Investors are actively discussing the token's value proposition in comparison to major platforms like Amazon, Google, and Microsoft, viewing KTA as a targeted bet on the future of financial plumbing. The community also highlights potential partnerships, particularly with Stripe, as a key catalyst.

Pump Mind Virus is a Pure Meme with a long term vision. We are building for the future while making no promises about the present. The project aims to bring the spirit of community memes back to the Solana ecosystem. We do that with engaging content and memes. Culture through community. Viral spread by word of mouth.  And most importantly, by not using the fake hype machine that has come to dominate the meme coin landscape.

PumpMindVirus

PumpMindVirus ($PMV) is trending as its community rallies around its "organic meme" culture and energetic online presence, creating a buzz and attracting attention within the crypto space. Community members emphasize their strong conviction and commitment to spreading the "infection," suggesting a shared belief in the project's potential. The coin is associated with the $PUMP ecosystem on $SOL, and the community is expressing excitement for the project's future.

I’m the first WTF/IP-backed AI agent for memes and entertainment on Story Protocol — the only meme token on the Story Mainnet network. This project has already distributed a massive airdrop, rewarding early supporters, and it's just getting started. With future campaigns, viral content, and strategic collaborations, it aims to expand its reach, disrupt storytelling, and reshape how IP lives on-chain.

Waterfall Governance

Waterfall Governance ($WTF) is trending as traders discuss its relationship with $SLAP. The community is actively trying to define the connection between $WTF and other tokens like $SLAP, while also considering its future potential within the broader cryptocurrency market.

Mason Capital Fund Trust - Fundamentals First ETF

KNOW is gaining attention, potentially linked to chatter about Nvidia ($NVDA) and a cryptic hand gesture possibly hinting at market direction. The community is actively speculating on the implications of this gesture, with some suggesting it's a sign that 'Nvidia knows' something significant. Amidst this, some investors are highlighting KNOW Labs' potential in non-invasive glucose monitoring and its possible NASDAQ listing.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>A rescue financing and loan settlement halted an impending asset seizure after Oxford’s default.</li><li>A two-stage preferred stock deal supplies up to $6 million to stabilize operations and restructure debts.</li><li>New turnaround-focused leadership was appointed as part of the recovery plan.</li></ul>Kala Bio surged 22% after hours on Tuesday after the company disclosed a rescue financing agreement that temporarily stabilizes its operations and averts a pending asset seizure by its lender. The move marks the company's reversal since September, when its eye disease therapy KPI-012 failed a Phase 2 trial, triggering a roughly 90% collapse in the stock and a wave of analyst downgrades.<h2 class="st-heading-2">Emergency Financing Steps In After Default</h2>The after-hours rally followed Kala’s filing detailing a sequence of events that began on Sept. 29, when Oxford Finance issued a notice of default under the company’s loan agreement and declared all obligations immediately due.&nbsp;On Oct. 19, Oxford informed Kala it intended to foreclose on all remaining assets,&nbsp;sweep all of the company’s cash, and&nbsp;restrict the use of funds to minimal payroll expenses necessary to execute the foreclosure. The same day, Kala terminated all remaining employees except those required to support Oxford’s process.Oxford later paused the foreclosure on Nov. 3 and allowed Kala to access $125,000 of previously swept cash to negotiate a potential transaction. On Nov.9, Kala executed a convertible loan agreement with investor David Lazar for $375,000 to fund&nbsp;the preparation of its quarterly filing and support negotiations for further investment.<h2 class="st-heading-2">Lifeline Private Placement Up To $6 Million</h2>The company then entered into a securities purchase agreement on Nov. 23 under which Lazar agreed to provide up to $6 million in a two-stage private placement of Series AA and Series AAA preferred stock. The first closing occurred on Monday, delivering $1.8 million to Kala. The second closing, for an additional $4.2 million, requires shareholder approval to increase authorized common shares and permit conversion of the preferred stock. Kala will hold the shareholder meeting before March 31, 2026. The proceeds will fund current operations, liabilities, and expenses, with $1 million of the second closing earmarked for Oxford as part of the settlement arrangement.<h2 class="st-heading-2">Settlement Restructures Obligations</h2>As part of the rescue package, Kala and unit Combangio entered into a loan settlement agreement with Oxford on Nov. 23. Oxford agreed to settle all outstanding payment obligations in exchange for a $2 million cash settlement and 1.62 million shares of common stock.&nbsp;Once Kala pays the initial $1 million and issues the settlement shares, Oxford will release control of Kala’s bank accounts, reduce the outstanding loan balance by $7 million, and waive associated interest and final payments. The company also agreed to pay Oxford 10% of future equity financing proceeds, up to $1 million, with each such payment reducing loan obligations by 3x the amount contributed.Oxford’s foreclosure efforts will formally end once the full settlement payment is completed. Kala is committed to pursuing a “material strategic alternative transaction” within one year to clear the remaining settlement balance.<h2 class="st-heading-2">Leadership Changes Accompany Restructuring</h2>As part of the financing deal, David Lazar was appointed CEO and elected to the board on Nov. 21. Lazar brings a turnaround-focused background to the role. He currently leads Custodian Ventures LLC and Activist Investing LLC, firms that specialize in turnaround situations involving distressed public companies.Todd Bazemore, the prior CEO, stepped down from the role but remains on the board. Meanwhile, chief financial officer Mary Reumuth was terminated effective immediately following the first closing, and the company also announced settlement agreements for certain former executives tied to their contractual severence rights.<h2 class="st-heading-2">Fallout From Eye Drug Trial Failure</h2>The crisis began in late September when KPI-012, a treatment for persistent corneal epithelial defect, failed to meet all primary and secondary endpoints in the Phase 2b CHASE trial. The miss contradicted the positive signals seen in the earlier Phase 1b trial and led management to terminate development of KPI-012 and its broader mesenchymal stem cell secretome platform. Analysts at Mizuho, H.C. Wainwright and LifeSci Capital downgraded the stock immediately afterward, citing the unexpected data and lack of disclosed details.&nbsp;<h2 class="st-heading-2">Stocktwits Users Cite David Lazar Upside For Kala Bio</h2>On Stocktwits, retail sentiment for Kala Bio was ‘extremely bullish’ amid ‘extremely high’ message volume.<figure class="image"><img style="aspect-ratio:970/140;" src="https://news.stocktwits-cdn.com/kala_ss_png_9a4902a4d7.webp" alt="kala ss.png" width="970" height="140"><figcaption>KALA sentiment and message volume as of November 26 | Source: Stocktwits</figcaption></figure>One bullish user said, “<a href="https://stocktwits.com/symbol/KALA">$KALA</a> 1.50 next leg. David Lazar play. new<a href="https://stocktwits.com/symbol/CETY"> $CETY</a>.”<stembedurl>https://stocktwits.com/CAPITALWHISPERER/message/637454686</stembedurl>Another user said, “Look what david Lazzar did to $opgen and find out why he make<a href="https://stocktwits.com/symbol/KALA"> $KALA</a> investors very rich if they are patient.”<stembedurl>https://stocktwits.com/Frederickquan/message/637468005</stembedurl><a href="https://stocktwits.com/symbol/KALA">Kala Bio’s stock</a> has declined 91% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Kala Bio’s stock (KALA) has declined 91% so far in 2025. (Photo credit: Getty Images)

Kala Bio Stock Soars 22% After Hours As Emergency Financing Deal Averts Asset Seizure After Eye Disease Drug Trial Collapse

A rescue financing and loan settlement halted an impending asset seizure after Oxford’s default.

Equity

KALA Stock Crashes 88% in a Month Following Eye Disorder Study Failure

KALA BIO stock plunges 88% after its KPI-012 eye disorder study fails to meet goals, forcing the company to scrap its pipeline and explore strategic options.

KALA BIO (KALA) announced on Monday that its KPI-012 failed in a mid-stage clinical trial evaluating it as a treatment for persistent corneal epithelial defect.A persistent corneal epithelial defect (PCED) is a corneal injury that fails to heal within the typical timeframe of two weeks, persisting for weeks or even months despite standard treatment. Kala’s study to evaluate the safety and efficacy of two doses of KPI-012 ophthalmic solution did not meet the primary goal of complete healing of PCED at week 8, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.kalarx.com/news-releases/news-release-details/kala-bio-announces-topline-results-chase-phase-2b-clinical-trial">said</a>. It also noted that the secondary goals in the study did not achieve statistical significance, and there was no meaningful difference between the KPI-012 treatment arm and the placebo arm in the trial.The company subsequently decided to cease clinical development of KPI-012 and stated that it is evaluating its strategic options. The firm noted that it intends to preserve cash, including by laying off some of its workforce and implementing other cost-saving measures.Kim Brazzell, Chief Medical Officer of Kala Bio, said that the company is “disappointed” to see the new study results.“KPI-012 continued to be well-tolerated and demonstrated a favorable safety profile but did not demonstrate the efficacy results that would warrant advancing the program for treatment of front-of-the-eye diseases,” he added.Shares of the company slipped 89% at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/KALA">KALA stock</a> rose to ‘extremely bullish’ from ‘neutral’ territory over the past 24 hours, while message volume rose to ‘extremely high’ from ‘high’ levels.Following the company’s announcement, LifeSci Capital downgraded Kala Pharmaceuticals to ‘Market Perform’ from ‘Outperform’ and removed the firm's price target on the stock.Mizuho analyst Graig Suvannavejh, meanwhile, expressed disappointment that the company did not share any data details or host a call to discuss the study results, as per TheFly. &nbsp;KALA stock is down by 69% this year and by about 62% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/dogwood-therapeutics-stock-soars-pre-market-on-securing-license-for-cancer-related-pain-management-drug/chDubC3R3J2">Dogwood Therapeutics Stock Soars Pre-Market On Securing License For Cancer-Related Pain Management Drug</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Kala Bio Stock Just Plunged 89% Today – Here’s What Happened

The firm stated that its KPI-012 failed in a mid-stage clinical trial and announced that it intends to preserve cash, including by laying off some of its workforce and deploying other cost-saving measures. 

Wall Street Analysts Believe KALA BIO (KALA) Could Rally 74.73%: Here's is How to Trade

The mean of analysts' price targets for KALA BIO (KALA) points to a 74.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks.com featured highlights include KALA, Graham, Arq and Hawkins

KALA, GHM, ARQ, and HWKN are drawing investor attention after fresh analyst coverage highlights improving outlooks.

Analyst Coverage Sparks Interest in These 4 Stocks Amid Volatility

New analyst coverage lifts investor interest in KALA, GHM, ARQ, and HWKN as markets grapple with rising volatility.

Shares of Kala Bio Inc. tumbled over 35% on Wednesday, on track for their worst single-day decline ever, after the company announced the resignation of CEO Mark Iwicki.President Todd Bazemore has been named interim CEO, while Iwicki will remain as chair of the board.&nbsp;Iwicki, who has led Kala for nearly a decade, oversaw multiple phases of drug development.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/KALA_sentiment_and_message_volume_on_Feb_12_cdc55fd016.png" alt="KALA sentiment and message volume on Feb 12.png" width="1318" height="324"><figcaption>KALA sentiment and message volume on Feb 12 as of 2 pm ET | source: Stocktwits</figcaption></figure>Despite the steep selloff, retail traders on Stocktwits believe the market reaction is excessive, as evidenced by the 'extremely bullish' sentiment score.&nbsp;One user argued that Iwicki's departure "is the best thing possible for this company" and could signal a potential sale of the company after Kala's upcoming pipeline update.<stembedurl>https://stocktwits.com/Stmkr/message/603965500</stembedurl><stembedurl>https://stocktwits.com/Sammysums/message/603977842</stembedurl>Kala is set to report mid-stage trial data in the second quarter for KPI-012, its experimental treatment for persistent corneal epithelial defects, a condition that can lead to vision loss.&nbsp;The company is also exploring KPI-012 for Limbal Stem Cell Deficiency and other rare corneal diseases, while its MSC-S platform is in preclinical studies for retinal degenerative conditions like Retinitis Pigmentosa and Stargardt Disease.At the end of 2024, Kala raised approximately $10.8 million through a private placement of common shares and Series I convertible preferred stock with institutional investors.The company is expected to report fourth-quarter earnings in March. Wall Street projects an adjusted loss per share of $2.28, down from $3.62 a year ago, on no revenue.Kala shares are down just 2.2% over the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Kala Bio Stock Sinks On CEO Exit, But Retail Feels It’s An Overreaction

Kala is set to report mid-stage trial data in the second quarter for KPI-012, its experimental treatment for persistent corneal epithelial defects.

KALA Stock Earnings: Kala Pharmaceuticals Beats EPS for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips
KALA stock results show that Kala Pharmaceuticals beat analyst estimates for earnings per share the fourth quarter of 2023.
The post...

Kala Pharmaceuticals GAAP EPS of -$3.18 beats by $0.44

Kala Pharmaceuticals GAAP EPS of -$3.18 beats by $0.44...

KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

-- Advancing ongoing Phase 2b CHASE trial of KPI-012 for PCED; topline data targeted by year-end 2024 ---- Exploring opportunities to expand KPI-012 into additional corneal indications ---- Cash...

Kala Bio, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of therapeutics using proprietary nanoparticle-based mucus penetrating particles with an initial focus on the treatment of eye diseases. The company was founded by Justin Hanes, Robert S. Langer and Colin R. Gardner in 2009 and is headquartered in Arlington, MA.

Kala Bio Inc.

$AMZN

$MSFT

$GOOGL

$ORCL

Which cloud infrastructure stock offers the best long-term opportunity right now?

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '25	-$1.70	-$1.71	-0.39%	MISSED
Q1 '25	-$2.03	-$1.41	30.54%	BEAT
Q4 '24	-$2.28	-$1.74	23.68%	BEAT
Q3 '24	-$2.43	-$1.93	20.58%	BEAT
Q2 '24	-$4.41	-$3.16	28.26%	BEAT

KALA
KALA BIO Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q1 '25

Historical Earnings

Latest KALA News

KALAKALA BIO Inc